Ray Therapeutics Raises $125M Series B to Advance Optogenetic Therapies for Vision Restoration

Ray Therapeutics just pulled $125M into the room and pointed it straight at one of medicine’s toughest conversations: what happens when vision fades and nothing on the shelf can stop it. This isn’t a thought experiment out of Berkeley, this is a clinical-stage company moving with intent, backed by capital that expects outcomes, not optics.

Janus Henderson Investors stepped in to lead, flanked by a table that reads like a capital markets roll call: Adage Capital Management, Franklin Templeton, Invus, Marshall Wace. Then you’ve got the return players who don’t scare easy: 4BIO Capital, Novo Holdings, Deerfield Management, Norwest, Platanus, MRL Ventures Fund. When that many repeat investors double down, it’s not optimism, it’s pattern recognition.

Paul Bresge, CEO, didn’t build Ray Therapeutics to admire the problem. The company is pushing optogenetic gene therapy into territory where most biotech conversations get uncomfortable. Mutation-agnostic vision restoration. Translation: instead of chasing every genetic permutation, they’re teaching surviving retinal cells a new trick…how to see again. Light in, signal out, brain back in the game.

The lead programs are already in motion. RTx-015 is stepping into the ring for retinitis pigmentosa with FDA RMAT designation in its corner. RTx-021 is targeting macular diseases like Stargardt and geographic atrophy AMD. These aren’t soft targets, these are the kind of conditions where patients are told to adapt, not expect reversal. Ray Therapeutics is betting against that narrative.

Now let’s talk about why this round actually matters beyond the headline number. This wasn’t just capital for curiosity. This was funding aimed squarely at late-stage clinical development and commercial readiness. That’s a different tone. That’s not “let’s see if it works,” that’s “let’s make sure it scales, gets approved, and reaches people who need it.”

There’s a lesson here that founders love to ignore until the market humbles them. Consistency compounds. Ray Therapeutics went from seed backing with 4BIO Capital to a $100M Series A to this $125M Series B. Same believers, bigger checks, tighter story. You don’t get that by being loud. You get that by being right, repeatedly, when it counts.

And for anyone building in biotech or beyond, take a second look at the strategy. Go where the unmet need is brutal. Build something that doesn’t just iterate, but rethinks the constraint entirely. Then surround yourself with capital that understands timelines measured in years, not hype cycles measured in tweets.